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Abstract
The endogenous peroxisome proliferator-activated receptor alpha (PPAR-a)
agonist Oleoylethanolamide (OEA) inhibits eating in rodents, mainly by delay-
ing the onset of meals. The underlying mechanisms of OEA-induced anorexia,
however, remain unclear. Animals treated with high OEA doses were shown
to display signs of discomfort and impaired locomotion. Therefore, we first
examined whether the impaired locomotion may contribute to OEA’s anorec-
tic effect. Second, it is controversial whether abdominal vagal afferents are
necessary for OEA’s anorectic effect. Thus, we explored alternative peripheral
neural pathways mediating IP OEA’s anorectic effect by performing a celiac-
superior mesenteric ganglionectomy (CGX) or a subdiaphragmatic vagal deaf-
ferentation (SDA) alone or in combination. Exogenously administered OEA at
a commonly used dose (10 mg/kg BW, IP) concurrently reduced food intake
and compromised locomotor activity. Attempts to dissociate both phenomena
using the dopamine D2/D3 receptor agonist Quinpirole (1 mg/kg BW, SC)
failed because Quinpirole antagonized both, OEA-induced locomotor impair-
ment and delay in eating onset. CGX attenuated the prolongation of the
latency to eat by IP OEA, but neither SDA nor CGX prevented IP OEA-
induced locomotor impairment. Our results indicate that IP OEA’s anorectic
effect may be secondary to impaired locomotion rather than due to physiolog-
ical satiety. They further confirm that vagal afferents do not mediate exoge-
nous OEA’s anorectic effects, but suggest a role for spinal afferents in addition
to an alternative, nonneuronal signaling route.
Introduction
To control energy intake and energy expenditure, com-
plex brain circuits integrate peripheral homeostatic sig-
nals. N-acylethanolamines, lipid-derived molecules with
an ethanolamide moiety, supposedly provide such signals
(DiPatrizio 2016). Oleoylethanolamide (OEA) is a fatty
acid ethanolamide synthesized from oleic acid, mainly in
the intestine in response to a fatty meal (Peterson et al.
2006; Fu et al. 2007, 2008; Schwartz et al. 2008). OEA has
been shown to potently reduce food intake in rodents
after peripheral administration (Rodriguez de Fonseca
et al. 2001; Fu et al. 2003; Gaetani et al. 2003) and was
therefore even suggested as a possible therapeutic agent to
fight obesity (Romano et al. 2014). In freely eating rats,
intraperitoneal (IP) or oral administration of OEA
reduces food intake mainly by prolonging the latency to
eat without affecting meal size or postmeal interval
(Rodriguez de Fonseca et al. 2001; Gaetani et al. 2003;
Azari et al. 2014). The results from pharmacological and
transgenic studies suggest that OEA’s anorectic action is
mediated by the peroxisome proliferator-activated
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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receptor alpha (PPARa) (Fu et al. 2003; Lo Verme et al.
2005; Peterson et al. 2006; Azari et al. 2013), but the exact
mechanism through which OEA inhibits eating is still
uncertain. Rodriguez de Fonseca et al. (2001) argued for
an involvement of sensory fibers of the abdominal vagus,
but recent studies from our laboratory (Azari et al. 2014)
challenge this concept. OEA still potently reduced food
intake in rats after subdiaphragmatic vagal deafferentation
(SDA), a surgical procedure that eliminates all abdominal
vagal afferents, while sparing half of the efferents.
Several studies indicate that OEA does not induce vis-
ceral illness or aversion (Proulx et al. 2005; Rodriguez de
Fonseca et al. 2001), but a high dose of IP OEA (20 mg/
kg) was shown to impair locomotor activity in rats, a
finding that was judged negligible in relation to the
reduction in food intake (Rodriguez de Fonseca et al.
2001). Years later, Wang and colleagues showed that IP
administered OEA in mice (25 mg/kg) produced pro-
nounced nociceptive behaviors (Wang et al. 2005), and
others noted a decrease in ambulation and increase in
inactivity time in rats following IP OEA (20 mg/kg)
administration (Proulx et al. 2005). Similar observations
in early stages of our work prompted us to investigate
whether this locomotor impairment may be relevant for
OEA’s anorectic effect. We attempted to dissociate the
latency to eat from the locomotor impairment to assess
the OEA-induced anorexia without confounding elements
by first delaying food access and second by pharmacologi-
cally rescuing locomotion. In this respect, the dopamine
D2/D3 agonist Quinpirole has been shown to increase
locomotor activity in doses above 0.5 mg/kg and after
60 min upon injection (Eilam and Szechtman 1989),
making it a pharmacologic candidate for restoring base-
line locomotion.
Also, the findings that intracerebroventricular adminis-
tration of OEA has no effect on food intake (Rodriguez
de Fonseca et al. 2001) and that vagal afferents are not
necessary for the anorectic effect of OEA (Azari et al.
2014) indicated an alternative peripheral, vagus nerve-
independent, mechanism of action. We therefore
examined whether spinal afferents (whose cell bodies are
localized in the dorsal root ganglia (DRGs)) may be
involved in conveying the OEA-derived anorectic signal.
By surgical removal of the majority of the spinal afferent
fibers connecting the gastrointestinal tract with the brain
(celiac superior mesenteric ganglionectomy, CGX), and
by combining the CGX procedure with the SDA, we
examined the necessity of gastrointestinal afferent nerves
(spinal and vagal) for IP administered OEA-induced
anorexia. Our results provide evidence for a causal rela-
tion between locomotor impairment and observed reduc-
tion in food intake and suggest an alternative,
nonneuronal, route of action for OEA.
Methods
Animals and housing
Male Sprague-Dawley rats (Charles River), weighing
160–180 g upon arrival, were housed individually in a
climate-controlled room (22  2°C and 55  5% relative
humidity) under a 12/12 h dark/light cycle with ad libitum
access to water and standard chow (Kliba 3436). All pro-
cedures were approved by the Veterinary Office of the
Canton of Zurich.
Drugs
Oleoylethanolamide (OEA) (Cayman n.90265) was dis-
solved in sterile saline/polyethylene glycol/tween 80 (90/5/
5 v/v, 2 mL/kg (BW) and infused at the dose of 10 mg/
kg BW through the IP catheter (1 min/mL) at the begin-
ning of food intake or locomotor activity recording,
unless otherwise stated. Quinpirole (Sigma Aldrich n.
Q102) was dissolved in saline and subcutaneously (SC)
injected at a dose of 1 mg/kg BW (1 mL/kg) 1 h prior to
OEA administration.
Catheter assembly
The catheters were in-house handmade as described ear-
lier (Azari et al. 2014). Briefly, the catheters consisted of
silicone tubing [Dow Corning,; inner diameter
(ID) 9 outer diameter (OD), 0.51 9 0.91 mm] con-
nected to a polished L-shaped 22-gauge needle (Sterican,
B. Braun). The connections between tubing and needles
were shielded with 3-mm (ID 9 OD, 0.76 9 1.65 mm)
and 2.2 cm (ID 9 OD, 1.02 9 2.18 mm) long pieces of
silicone tubing as inner and outer layers, respectively.
Surgery preparations
All surgeries were performed under aseptic conditions.
Prior to surgery, rats received a SC injection of antibiotics
(20 mg/kg BW of sulfadoxine, Borgal 24%; Intervet/Sher-
ing-Plough) for infection prophylaxis. An IP injection of
atropine (0.05 mg/kg BW; Sintetica) was given before rats
were anesthetized by isoflurane. Postoperative care con-
sisted of antibiotics (1 day) and analgesic treatment
(2 days).
IP catheter implantation
The proximal end of the catheter was led subcutaneously
from the neck to a midline incision in the abdomen and
inserted in the abdominal cavity through a puncture hole.
Intraperitoneal catheters ended in the peritoneal cavity
2018 | Vol. 6 | Iss. 3 | e13517
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and were anchored on the left side of the abdominal wall
with Histoacryl glue (B. Braun Medical).
Subdiaphragmatic vagal deafferentation
The Subdiaphragmatic vagal deafferentation (SDA) sur-
gery was adapted from the method established by Nor-
gren and Smith (1994) as described in detail previously
(Arnold et al. 2006; R€uttimann et al. 2009). Briefly, it
consisted of a left-side intracranial vagal rhizotomy and a
transection of the dorsal (right) subdiaphragmatic trunk
of the vagus nerve. The SDA results in a complete discon-
nection of the abdominal afferents, while sparing half of
the abdominal vagal efferents. SDA completeness was ver-
ified using an established functional test ascertaining the
lack of cholecystokinin (CCK) satiation that depends on
intact abdominal vagal afferent fibers (Smith and Gibbs
1985). Based on this criterion, we excluded two animals
from the final analysis.
Celiac superior mesenteric ganglionectomy
As described by Sclafani et al. (2003), a 4–5 cm incision
on the left side of the midline was performed and the left
kidney, head of the spleen and pancreas were identified.
Organs were gently retracted, overlying connective tissue
was removed by blunt dissection, and the superior celiac
ganglion was exposed. Localized between the descending
aorta, celiac artery, and mesenteric artery, it assumes a
star-shaped structure with radiating processes. The radia-
tions were identified and carefully cut to allow ganglion
removal. Any additional neural tissue along the aorta,
celiac artery and cranial mesenteric artery in the consid-
ered area was also transected. Celiac superior mesenteric
ganglionectomy (CGX) completeness was confirmed by
measuring the norepinephrine (NE) levels in intestinal tis-
sues, and no animals were excluded. Some animals under-
went the combination of SDA and CGX, without
displaying any complication. Sham surgery consisted of
exposing the vagal rootlets and dorsal subdiaphragmatic
vagus similarly to the SDA procedure, but without
manipulating them, combined with the exposure without
further alteration of the celiac-mesenteric ganglion.
Food intake measurement and meal pattern
analysis
Grounded chow (Kliba 3433) was available through a
niche from feeding containers placed on scales (XS4001S;
Mettler-Toledo) connected to a computer with custom-
designed software (LabX meal analyzer 1.4, Mettler-
Toledo) that continuously recorded food intake. Meals
were defined as food removals ≥0.3 g separated by
≥15 min of noneating as described previously by us and
others (Farley et al. 2003; Azari et al. 2013; Punjabi et al.
2014) The satiety ratio was defined as the ratio between
the first postmeal interval (min) and the first meal size
(g). For food intake experiments, rats were food deprived
for 1 hour and re-fed at dark onset.
Two bottles conditioned taste avoidance
test:
Animals were adapted for 6 days to a daily water depriva-
tion schedule with 2 h water access at the end of the light
phase. Water was presented in two different bottles whose
location was randomized during the adaptation period.
Animals had ad libitum access to food. On the condition-
ing day, animals were offered for 30 min a 0.125% sac-
charin solution prior to infusion of NaCl (control), LiCl
(60 mg/kg/9.4 mL in water) or OEA (10 mg/kg). Water
was then offered for additional 90 min. After one inter-
vening day, on which water was again presented for 2 h,
on the test day, one bottle of water and one bottle of the
saccharin solution were offered at random locations and
30 min intakes were recorded.
Open field test
The test was carried out in two identical square arenas
(80 9 80 cm) surrounded by walls 50 cm high, and a
digital camera was mounted directly above the two are-
nas. The open field apparatus was made of grey Plexiglas
and was located in a testing room under diffused lighting
(30 lux as measured in the center of the arenas). Images
were transmitted to a PC running the EthoVision (Noldus
IT) tracking system. All tests were carried out during the
dark phase and lasted 30 min. Experimenters who were
blinded to the treatments analyzed the recorded video
tapes for abdominals writhes: an arching of back, exten-
sion of hind limbs, and contraction of abdominal muscu-
lature and lateral torsions: an unnatural lateral
displacement of the body weight on two limbs.
Tissue collection and gene expression
Animals received an IP infusion of pentobarbital-Na
(100 mg/kg; Cantonal Pharmacy Zurich) 60 min after
OEA or vehicle were infused, and the nodose ganglia
(NG), DRGs (T5-T11), and duodenum were promptly
collected, frozen in liquid nitrogen and stored at 80°C.
NGs and DRGs from the same animal were pooled before
RNA was extracted using Trizol (Life Technologies). RT-
quantitative PCR (qPCR) was performed using SybR
Green on a OneStep Plus instrument (Applied Biosys-
tems), and results were analyzed, using the 2ddCt
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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method. The following qPCR primers were used: cfos:
F- AGCATGGGCTCCCCTGTCA, R- GAGACCAGAGTG
GGCTGCA and Neuron-specific enolase (Eno2): F- G
GGGCACTCTACCAGGACTT, R- GGTCGAATGGGTC
TTCAATG.
Statistical analysis
All statistical analyses were performed using GraphPad
prism (v .7.02 for Windows). When data were normally
distributed (Shapiro–Wilk test), outliers were detected,
using the Rout test. Differences were analyzed using Stu-
dent t test for unpaired normally distributed values of
equal variance (Figs. 1J–K, 2A, C, E–I and 5) or a Mann–
Whitney U test for unpaired comparison of nonnormally
distributed data (Fig. 2D). For samples/groups >2, differ-
ences were analyzed by a one-way ANOVA if normality
criteria were met (Fig. 1B, D–I), otherwise by the
Kruskal–Wallis test (Fig. 1C). Multiple comparisons were
assessed with Dunn’s test. Where the dependent variable
was affected by two factors, data were analyzed with a
two-way ANOVA, (Figs. 1A,L, 2B, 3 and 4). For post hoc
analyses, the Bonferroni/Sidak correction was used. Data
are presented as means  SEM. P values <0.05 were con-
sidered significant.
Results
Exogenously administered OEA concurrently
reduced food intake and locomotor activity
but did not induce avoidance
In line with previous findings (Rodriguez de Fonseca
et al. 2001; Fu et al. 2003; Gaetani et al. 2003), 5 and
10 mg/kg BW OEA reduced food intake of freely eating
rats compared to vehicle, 1 and 4 h after IP infusion,
whereas 1 mg/kg OEA reduced food intake only at 4 h
after injection (Fig. 1A). Food intake of all OEA infused
animals was similar to food intake of control animals at
8, 12 and 24 h after infusion (Fig. 1B). Five and 10, but
not 1 mg/kg BW OEA prolonged the latency of eating
onset after infusion compared to controls (48.5  15 and
63  7 min vs. 2  1 min, mean  SEM) (Fig. 1C). Five
and 10 mg/kg OEA did not affect first meal size, average
meal size, number of meals, intermeal intervals nor the
satiety ratio compared to controls, but 1 mg/kg OEA
affected satiety ratio and intermeal interval. We then
assessed the effects of OEA on the animals’ locomotor
behavior by measuring their activity for 30 min in an
Open Field arena. This test revealed that both doses of 5
or 10 mg/kg of OEA reduced the total distance moved
compared to vehicle (Fig. 1I). Furthermore, OEA elicited
abnormal motor behaviors, here defined as “abdominal
writhes” and “lateral torsions”, absent in control animals
(Fig. 1J–K) (Video S1) and without, as described previ-
ously (Rodriguez de Fonseca et al. 2001; Proulx et al.
2005), inducing conditioned avoidance (Fig. 1L).
Delaying food access for 1 h after injection
prevented OEA’s effects on food intake and
locomotion
To test whether the prolonged latency to eat and, hence,
the reduced food intake in response to OEA might be
related to the impaired locomotion, we evaluated the
effects of OEA on food intake when animals did not have
access to food for the first hour after infusion, once loco-
motion was no longer impaired. We first verified that one
hour after OEA infusion the animals’ motility was no
longer affected (Fig. 2A) and then analyzed their eating
behavior. Under these conditions, 10 mg/kg OEA did not
affect food intake compared to vehicle infusion (Fig. 2B
and C), and no difference in latency to eat (Fig. 2D) or
eating patterns (Fig. 2E and I) was observed. This indi-
cates that the anorectic effect of IP OEA (10 mg/kg BW)
does not persist after locomotor impairments have
stopped. It suggests a possible causal relation between
impaired locomotion and latency to eat.
Figure 1. OEA infusion reduced short-term food intake, prolonged latency to eat and impaired locomotor activity without inducing avoidance.
(A–H) food intake and meal pattern analysis after OEA (1, 5, 10 mg/kg BW) or veh administration (n = 8). Short-term (4 h) food intake (A), 2-
way ANOVA, group F(3,28) = 4.695, P < 0.01, time F(3,84) = 138.2, P < 0.01, group 9 time F(9,84) = 3.509 P < 0.01 followed by Tukey’s
multiple comparison test (a = veh vs. 5, 10 mg OEA P < 0.05; b = veh vs. 1, 5, 10 mg OEA, P < 0.001). 24 h food intake (B), ANOVA ns.
Latency to eat (C), Kruskal–Wallis P < 0.05, followed by Dunn’s multiple comparison test. First meal size (D), average meal size (E) and number
of meals (F), ANOVA, ns. Satiety ratio (G) and intermeal interval (between first and second meal) (H), ANOVA, respectively, ns and P < 0.05,
followed by Tukey’s multiple comparison test. (I–K) open field test recordings after OEA (1, 5, 10 mg/kg BW) or veh administration (n = 5).
Total distance moved in 30 min (I), ANOVA, P < 0.01 followed by Tukey’s multiple comparison test. OEA-induced motor behaviors: number of
lateral torsions (J) and number of abdominal writhes (K), Student’s t-test, P < 0.05 and P < 0.01, respectively. (L) Saccharin preference ratio
(saccharin solution intake in % of total fluid) after veh, (n = 6) LiCl (n = 3) or OEA (10 mg/kg, n = 8). 1-way ANOVA, P < 0.05, followed by
Tukey’s multiple comparison test. Results are presented as means  SEM. veh = vehicle, ns = statistically not significant, *P < 0.05, **P < 0.01,
***P < 0.001.
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Pretreatment with the dopamine D2/D3
receptor agonist Quinpirole antagonized the
locomotor impairment and the delay in
eating onset caused by OEA
To examine further whether the delayed eating onset
might be causally related to the compromised
locomotion, we pretreated the rats with the dopamine
D2/D3 receptor agonist Quinpirole in an attempt to pre-
vent the OEA-induced inhibition of locomotion. Quin-
pirole prevented OEA from causing a significant
reduction in horizontal activity compared to vehicle:
while OEA significantly affected locomotion in saline-pre-
treated rats, it failed to do so in rats infused with
Figure 2. OEA did not affect locomotor activity or food intake when measurements started 1-h postadministration. (A) locomotor activity in an
open field test 1-h post-OEA (10 mg/kg BW) or veh administration (n = 10), Student t-test, ns. (B–I) food intake and meal pattern analysis 1-h
post-OEA (10 mg/kg BW) or veh administration (n = 10). Short-term (4 h) food intake (B), 2-way ANOVA, group F(1,9) = 1.497 ns, time F
(3,27) = 124.9 P < 0.01, group 9 time F(3,27) = 1.589 ns. 24 h food intake (C), Student t-test, ns. Latency to eat (D), Mann–Whitney U test,
ns. First meal size (E), average meal size (F), number of meals (G) satiety ratio (H), intermeal interval (I), Student t-tests, all ns. Results are
presented as means  SEM. veh = vehicle, ns = not statistically significant.
2018 | Vol. 6 | Iss. 3 | e13517
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Quinpirole (Fig. 3A). Likewise, OEA again prolonged the
latency to eat in control animals, but not in Quinpirole-
treated animals (Fig. 3B). In line with other findings
(Kuo 2001), Quinpirole did, however, reduce 24 h food
intake compared to saline injected controls, independent
of the OEA treatment (Fig. 3C).
Neither subdiaphragmatic vagal
deafferentation nor celiac superior
mesenteric ganglionectomy or the
combination of both procedures eliminated
the motor impairment or reduction in food
intake by OEA
To shed further light on the route engaged in IP OEA’s
signaling to the brain, we first determined whether the
OEA-induced motor dysfunctions were still present in
SDA animals and then evaluated the potential involve-
ment of spinal afferents. To do so, we used the estab-
lished SDA and CGX models and assessed IP OEA’s
effects on food intake and locomotion. Infusion of
10 mg/kg BW OEA resulted in a comparable reduction in
locomotion in all surgery groups (Fig. 4A). OEA also still
affected short-term food intake to different degrees and at
various time points in all groups (Fig. 4B) including the
24 h food intake in the SDA group (Fig. 4C). The delayed
onset of eating was still present in Sham, SDA and
SDA + CGX animals, but did not reach significance in
CGX animals (Fig. 4D). Again, OEA had no effect on the
animals’ eating patterns (first meal size, average meal size,
number of meals, intermeal interval or satiety ratio),
independent of the surgical procedure (Fig. 4E–I). Similar
to the findings with OEA, the exogenous PPARa agonist
WY-14643 affected the latency to eat and short-term food
intake in all surgical groups without altering other meal
pattern parameters (data not shown).
OEA induced an increase in c-Fos mRNA in
the nodose ganglia but not in dorsal root
ganglia
To investigate further whether spinal and/or vagal fibers
are recruited for OEA’s signaling, although they are not
required for the locomotor impairments, we quantified by
RT-qPCR the mRNA levels of c-Fos, a marker of neuronal
activation, in NGs and DRGs 45 min after IP OEA infu-
sion. This analysis revealed an upregulation of c-Fos
mRNA in NGs of OEA-treated animals compared to vehi-
cle (Fig. 5). No difference was detectable in DRGs.
Discussion
This study aimed at extending our understanding of
intraperitoneal-OEA (IP OEA)’s anorectic effect by: (1)
investigating, so far largely ignored, locomotor side effects
of IP OEA that might influence its anorectic action, and
(2) exploring possible peripheral neural pathways for IP
OEA’s signaling to the central nervous system. We show
Figure 3. Quinpirole pretreatment blunted the OEA-induced locomotor inactivity and prolonged latency to eat. All animals (n = 5 [A] n = 8
[B–C],) were pretreated with Quinpirole (1 mg/kg BW) or saline 1 h prior to OEA (10 mg/kg BW) or veh administration. Total activity in an
open field test (A), 2-way ANOVA, main effect of treatment (veh/OEA) F(1,16) = 6.119 P < 0.05, pretreatment (sal/qui) F(1,16) = 0.01376 ns,
treatment 9 pretreatment F(1,16) = 3.204, P = 0.09 followed by Bonferroni’s post hoc test. Latency to eat (B), 2-way ANOVA, main effect of
treatment (veh/OEA) F(1,28) = 14.12, P < 0.01, pretreatment (sal/qui) F(1,28) = 0.07442 ns, treatment 9 pretreatment F(1,28) = 4.136,
P = 0.05 followed by Tukey’s post hoc test. 24 h food intake (C), main effect of pretreatment (sal/qui) F(1,28) = 61.89, P < 0.01, treatment
(veh/OEA) F(1,28) = 0.058, ns, treatment 9 pretreatment F(1,28) = 4.969, P < 0.05, followed by Sidak’s post hoc test. Results are presented as
means  SEM. qui, Quinpirole, sal, saline, veh, vehicle, ns, not statistically significant, *P < 0.05, ****P < 0.0001.
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society
2018 | Vol. 6 | Iss. 3 | e13517
Page 7
S. Fedele et al. OEA’s Effects on Behavior
Figure 4. OEA still affected food intake and locomotor activity in CGX, SDA and SDA + CGX animals. (A) locomotor activity measurements in
an open field test in Sham, SDA, CGX or SHAM + CGX animals (n = 9 per surgery group) after infusion of 10 mg/kg BW OEA or veh, 2-way
ANOVA, treatment F(1,36) = 89.86 P < 0.01, surgery F(3,36) = 0.6705 ns, group 9 surgery F(3,36) = 2.961 P < 0.05. (B–I) food intake
measurements in Sham, SDA, CGX or SHAM + CGX animals (n = 8/9 per surgery group) after administration of 10 mg/kg BW OEA or veh.
Short-term (4 h) food intake (B) sham: 2-way ANOVA, treatment F(1,7) = 13.43 P < 0.01, time (3,21) = 92.9 P < 0.01, treatment 9 time F
(3,21) = 6.047 P < 0.01; CGX: treatment F(1,7) = 22.57 P < 0.01, time F(3,21) = .87 P < 0.01, treatment 9 time F(3,21) = 6.091 P < 0.01;
SDA: treatment F(1,32) = 65.45 P < 0.01, time F(3,32) = 10.54 P < 0.01, treatment 9 time F(3,32) = 10.17 P < 0.01; SDA + CGX: treatment
F(1,31) = 13.54 P < 0.01, time F(3,31) = 60.44 P < 0.01, treatment 9 time F(1,31) = 1.61 ns. 24 h food intake (C), 2-way ANOVA, treatment
F(1,30) = 9.979 P < 0.01, surgery F(3,30) = 2.208 ns, treatment 9 surgery F(3,30) = 12.46 ns. Latency to eat (D), 2-way ANOVA, treatment F
(1,30) = 102.8 P < 0.01, surgery F(3,30) = 4.521 P < 0.01, treatment 9 surgery F(3,30) = 5.047 P < 0.01. First meal size (E), 2-way ANOVA,
treatment F(1,30) = 0.4848 ns, surgery F(3,30) = 1.05 ns, treatment 9 surgery F(3,30) = 1.222 ns. Average meal size (F), 2-way ANOVA,
treatment F(1,30) = 0.01004 ns, surgery F(3,30) = 1.984 ns, treatment 9 surgery F(3,30) = 0.532 ns. Number of meals (G), 2-way
ANOVA, treatment F(1,31) = 3.678 ns, surgery F(3,31) = 6.533 P < 0.01, treatment 9 surgery F(3,31) = 0.988 ns. Satiety ratio (H), treatment F
(1,29) = 0.074 ns, surgery F(3,29) = 0.1273 ns, treatment 9 surgery F(3,29) = 1.17 ns. Intermeal interval (I), treatment F(1,30) = 5.792
P < 0.05, surgery F(3,30) = 0.48 ns, treatment 9 surgery F(3,30) = 1.082 ns. When the main effect or interaction terms were significant,
Sidak’s post hoc analyses were performed. Results are presented as means  SEM. veh, vehicle; SDA, subdiaphragmatic vagal deafferentation;
CGX, celiac superior mesenteric ganglionectomy; ns, not statistically significant, *P < 0.05, ***P < 0.001, ****P < 0.0001.
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that the commonly used anorectic dose of IP OEA
(10 mg/kg) impaired locomotion and evoked abnormal
motor behaviors that are concurrent to OEA’s anorectic
effect. Furthermore, our attempts to isolate OEA-induced
anorexia from the locomotor impairments remained
unsuccessful: neither delaying food access until locomotor
impairments stopped, nor a pharmacological rescue of
the locomotor impairments, dissociated these two phe-
nomena, suggesting that the IP OEA-induced anorexia is
probably due to locomotion impairment. In addition, we
show that these effects were unrelated to conditioned
avoidance, did not require intact abdominal vagal affer-
ents and were not completely absent in animals whose
intestinal splanchnic nerves were transected. Our data
indicate that spinal afferents and an impaired locomotion
may both contribute to IP OEA-induced anorexia.
IP OEA has been shown to reduce food intake in fed
and fasted rodents kept on chow or high fat diet (HFD).
However, in food-deprived rats IP OEA also decreased
meal size (i.e., caused satiation) (Gaetani et al. 2003;
Azari et al. 2014), in ad libitum fed rats, the anorectic
effect was almost exclusively due to a prolonged latency
to eat (Rodriguez de Fonseca et al. 2001; Gaetani et al.
2003; Azari et al. 2014). We observed similar effects of IP
OEA on meal patterns under our conditions: in ad libitum
chow-fed rats, IP OEA selectively prolonged the latency
to eat, an effect confined to the first 60 min after OEA
infusion (IP OEA (10 mg/kg) postponed eating onset by
63  7 min compared to vehicle). Furthermore, we
observed that during the time window in which the ani-
mals did not approach food, they displayed impaired
locomotor activity, reflected by a decrease in total
mobility, associated with abnormal motor behaviors such
as abdominal writhes and lateral torsions. These observa-
tions are in line with previous findings of experiments
(Proulx et al. 2005; Wang et al. 2005) in which OEA
bought from different sources was used in comparable
doses (5–20 mg/kg in rats) and dissolved in a similar way
(5% Tween 80, 5% propylene glycol, and 90% physiologi-
cal saline). Because of the transient nature of the observed
abnormal behaviors, it appears possible that several stud-
ies that did not describe such behaviors after IP-OEA
simply did not notice these transient phenomena.
Our findings, as well as a series of data collected by
other groups (Rodriguez de Fonseca et al. 2001; Proulx
et al. 2005), indicate that the IP OEA-induced anorexia is
not due to conditioned avoidance. As such tests are very
sensitive to disturbed wellbeing, the lack of conditioned
avoidance virtually excludes that IP-OEA inhibits eating
by inducing overall sickness or malaise. It is therefore
interesting that IP OEA at anorectic doses impaired loco-
motion. In addition, if we started to record activity 1-h
post-IP OEA infusion, we did not detect any locomotion
impairment. Likewise, if we prevented access to food until
1 h after infusion, OEA did not affect the latency to eat
or cumulative food intake, raising the possibility of a cau-
sal relation between impaired locomotion and prolonged
latency to eat. To further examine this possibility, we pre-
treated rats with the dopamine D2/D3 agonist Quinpirole
in an attempt to restore motor activity in OEA-infused
animals to a comparable level of vehicle-infused animals,
as Quinpirole was shown to increase motor activity. This
was supposed to allow for the examination of OEA’s
effects on eating in animals with uncompromised loco-
motion. In our setting, Quinpirole prevented the motor
impairment for the first 20 min after IP OEA and attenu-
ated the prolongation of the latency to eat by IP OEA.
These findings support the assumption of a causal rela-
tionship between hypolocomotion and anorexia.
Nonetheless, our attempts to dissociate the impaired loco-
motion from the anorectic effects (by delaying food access
or by pharmacologic intervention with Quinpirole) were
imperfect; in one case we may have missed the anorectic
effect OEA may have in the first hours after administra-
tion, and in the latter we found that Quinpirole itself had
an effect on food intake. Although these results do not
conclusively answer whether the IP-OEA-induced anorec-
tic effect recapitulates physiological satiety, they raise
serious questions about the physiological relevance of IP
OEA-induced anorexia.
While we co-administered OEA with Quinpirole simply
in an attempt to restore normal locomotion after OEA
administration, a possible involvement of dopamine in
the signaling cascade of OEA cannot be ruled out. Several
studies have suggested a link between OEA and the
Figure 5. OEA induced the expression of c-fos m-RNA in Nodose
Ganglia. Relative expression of c-fos mRNA in NG and DRGs
45 min after veh or OEA (10 mg/kg BW) treatment. (n = 7/8). NG:
Student t test, P < 0.05; DRG: Student t-test, ns. Results are
presented as means  SEM. veh, vehicle; NG, nodose ganglia;
DRG, dorsal root ganglia; ns, not statistically significant; *P < 0.05.
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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dopamine system (Melis et al. 2008; Luchicchi et al. 2010;
Tellez et al. 2013; Hankir et al. 2017). The proposed
mechanism involves a nongenomic effect of the PPARa
receptor activation, which would activate protein kinases
responsible for the phosphorylation status of the nicotinic
acetylcholine receptors (nAChRs) modifying the response
of dopaminergic neurons to nicotine (Melis et al. 2008;
Luchicchi et al. 2010). Together, these findings raise the
possibility that pharmacologic amounts of IP OEA,
through the PPARa-nAChR-DA receptor cascade, alter
the firing rate of DA, thus inducing the typical OEA-
dependent motor abnormalities, which are prevented
when the DA D2/D3 receptor agonist Quinpirole is
administered. Further support for this possibility, and in
particular for a role of PPARa in this context, is derived
from the fact that animals treated with the exogenous
PPARa agonist WY-14643 showed similar eating patterns
(Azari et al. 2013) and, based on our observations,
appeared to display similar effects on locomotor activity
as animals treated with OEA.
As a known agonist of PPARa, OEA’s role in modulat-
ing lipid metabolism has been extensively characterized. It
promotes lipid utilization and catabolism (Guzman et al.
2004), increases ketone body production (Guzman et al.
2004; Azari et al. 2013) and decreases liver triglyceride
and cholesterol levels (Fu et al. 2005). Furthermore, OEA
stimulates lipid translocation (Fu et al. 2003), and lipid
uptake and intracellular transport (Yang et al. 2007). All
these findings are in line with the notion that enterocytes
produce OEA in response to a fatty meal (mainly upon
ingestion of oleic acid) (Artmann et al. 2008). Once intra-
cellular OEA reaches the concentration of 300-400 lmol/
L, it activates the PPARa receptor (Schwartz et al. 2008),
one of the key regulators of lipid metabolism. While these
findings seem to reflect a physiological effect of OEA, our
data question the concept that the inhibition of eating by
exogenous OEA recapitulates such a physiological effect.
Rather, our findings suggest that the observed decrease in
food intake is secondary to the impaired locomotion
observed in response to IP OEA at pharmacological doses.
Under these conditions, any residual physiological anorec-
tic effect of OEA would be masked by, and difficult to be
discriminated from, the pharmacological side effect.
It was reported that OEA’s anorectic effect requires vagal
afferents (Rodriguez de Fonseca et al. 2001; Fu et al. 2003;
Tellez et al. 2013). In support of this idea, OEA activated
vagal afferent neurons in cultures of nodose ganglia neu-
rons (Wang et al. 2005). We showed that IP administra-
tion of OEA-induced c-Fos activation in rats’ nodose
ganglia in vivo, strengthening the notion that OEA can sig-
nal through abdominal vagal fibers. Nevertheless, the
OEA-induced reduction in food intake and the OEA-
induced locomotor incapacitation, both, were still present
in our SDA animal model that has no vagal afferents from
below the diaphragm left (Norgren and Smith 1994;
Arnold et al. 2006). This confirms previous findings from
our laboratory (Azari et al. 2014) and indicates that intact
abdominal vagal afferents are not necessary for the anorec-
tic effect of IP administered exogenous OEA. Of course
this does not exclude the possibility that a potential physi-
ologically relevant metabolic or satiating effect of OEA
may be mediated through the vagus nerve. More so as
vagal afferent neurons express PPARa (Liu et al. 2014).
Yet, the very strong effects of OEA on the latency to eat
associated with the locomotor incapacitation do not
require intact vagal afferents, are presumably not physio-
logical, and might mask any residual physiological satiating
effect that IP OEA may have. Because in SDA rats, IP
OEA’s anorectic effect was still present we attempted to
shed light on OEA’s route of action, by investigating the
potential involvement of spinal afferent fibers. All our sur-
gical groups (Sham, SDA, CGX, SDA + CGX) displayed
the characteristic IP OEA-induced locomotor impairment,
but IP OEA affected their eating behavior to different
degrees. The IP OEA-induced reduction in food intake was
still present after 24 h in SDA animals. This suggests that
interfering with vagal fibers would enhance the IP-OEA
effect on eating. We have no plausible explanation for this
phenomenon and can only speculate that by altering the
vagal innervation of the gastrointestinal tract, we may
induce some imbalance in the gut-brain axis and the
enteric nervous system that makes these animals more sen-
sitive to the effects of IP OEA. Furthermore, CGX animals
treated with OEA showed an attenuated prolongation of
the latency to eat. The short-term effect of IP OEA on
cumulative food intake was still present, but also reduced
in CGX animals. These data suggest that IP OEA may pro-
long the latency to eat in part via spinal afferents and in
part via the motor incapacitation, which does not seem to
require intact splanchnic afferents. We also showed,
though, that IP OEA did not lead to an up-regulation of c-
Fos in the DRGs, which argues against an activation of the
spinal fibers by OEA. Furthermore, the CGX surgery is not
specific for spinal afferents but also damages sympathetic
efferents, potentially modifying the normal physiology of
the gastrointestinal tract. Thus, further studies should
critically examine whether there could be any other, non-
specific effect of CGX that might antagonize the prolonga-
tion of the latency to eat by IP OEA. Either way, while a
neural route for OEA signaling cannot be excluded, IP
OEA may also act on the brain stem by reaching the area
postrema through the blood stream. This interpretation
would be in line with the increase in c-Fos in the AP
observed after IP OEA (Romano et al. 2017).
A last consideration is that in our set of experiments
we focused on the dose of 10 mg/kg as the rat studies
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that reported an anorectic effect of OEA, suggesting
that this effect may be physiologically relevant,
employed doses ranging from 5 to 20 mg/kg (Rodriguez
de Fonseca et al. 2001; Fu et al. 2003; Gaetani et al.
2003). Yet, the dose of 1 mg/kg OEA, which does not
impair locomotion while reducing 4 h food intake and
affecting satiety ratio and intermeal interval, could actu-
ally be the most appropriate dose to employ in future
rat experiments addressing the physiological relevance
of exogenous OEA.
In sum, our findings show that IP OEA, at the dose
that in our hands as well as in previous studies (Fu et al.
2003; Gaetani et al. 2003; Azari et al. 2014), reliably
reduces food intake, causes locomotor incapacitation,
which is the likely cause of the observed OEA-induced
anorexia under the conditions tested. The dissociation of
this locomotor impairment from the effects on food
intake is crucial to address the mechanisms of any physio-
logical eating-inhibitory effect of this compound.
Our findings are therefore important and require fur-
ther investigation with respect to mechanistic explana-
tions of the anorectic effect of exogenous OEA, even
more so in light of its potential effects on the dopamine
system and its cannabinoid-like nature.
Perspectives and Significance
Our findings highlight the fact that IP administration of a
commonly used dose of OEA transiently but strongly
impairs locomotion in addition to inhibiting eating. This
indicates that IP OEA does not simply recapitulate the
effects of endogenous OEA and, hence, questions the suit-
ability of IP OEA to investigate a putative physiological
satiating effect of endogenous OEA. Further, our data
question the suitability of using OEA as a pharmacother-
apy for weight control. In any case, the effects of IP OEA
require further characterization.
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Video S1: Effects of intraperitoneally (IP) Oleoylethanola-
mide (OEA) on the locomotion of rats. The rat on the
left panel was infused IP with 10 mg/Kg body weight of
OEA just prior to the video recordings. These side effects
are confined to the first 45–60 min post OEA infusion.
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